ion. Thus, there is a
substantial need for a test that enhances the ease and accuracy of melanoma
detection.
About DermTech:
Headquartered in La Jolla, California, DermTech International is
focused on the development and validation of molecular tests using
specimens obtained from the skin. The company's proprietary Epidermal
Genetic Information Retrieval (EGIR(TM)) technology is in clinical studies
to evaluate its potential as a non-invasive diagnostic for melanoma and
other major diseases. It is also being studied in the context of tracking
treatment efficacy for a variety of dermatologic and other conditions,
including the effects of drugs on skin at the molecular level in advance of
observable clinical results. DermTech is actively pursuing research using
EGIR and its applications in the areas of melanoma, prostate cancer and
various skin disorders, such as psoriasis. For additional information visit
http://www.dermtech.com
Contacts:
DermTech
George Schwartz
CEO
858.450.4222
For DermTech
Jennifer Larson
415.409.2729
jlarson@labfive.com
'/>"/>SOURCE DermTech Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board2.
DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma3.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients4.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain5.
Kline Study: Better Brushing Habits Boost European Oral Care Sales6.
Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia7.
NASA study will help stop stowaways to Mars8.
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome9.
Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer10.
Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 20111.
Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes